These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38545965)

  • 1. Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
    Schlueter M; Nestler-Parr S
    J Comp Eff Res; 2024 May; 13(5):e230165. PubMed ID: 38545965
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.
    Watt M; Malmenas M; Haeussler K
    J Comp Eff Res; 2024 May; 13(5):e240041. PubMed ID: 38606574
    [No Abstract]   [Full Text] [Related]  

  • 3. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
    Watt M; Malmenäs M; Romanus D; Haeussler K
    J Comp Eff Res; 2023 Jun; 12(6):e220188. PubMed ID: 37218553
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.
    Suffritti C; Sartorio S; Berra S; Janu VP; Caccia S; Zanichelli A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):963-965.e1. PubMed ID: 36379410
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.
    Bouillet L; Bocquet A; Belbezier A; Boccon-Gibod I
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):391-392. PubMed ID: 34082125
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of the safety and effectiveness of berotralstat for patients with hereditary angioedema: Report of six cases.
    Takamura S; Nakamura K; Fukuda T
    J Dermatol; 2023 Nov; 50(11):1506-1508. PubMed ID: 37721445
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.
    Belbézier A; Boccon-Gibod I; Bouillet L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2490-2491. PubMed ID: 33556593
    [No Abstract]   [Full Text] [Related]  

  • 8. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
    Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
    Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
    [No Abstract]   [Full Text] [Related]  

  • 9. Lanadelumab: First Global Approval.
    Syed YY
    Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary Angioedema.
    Busse PJ; Christiansen SC
    N Engl J Med; 2020 Mar; 382(12):1136-1148. PubMed ID: 32187470
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
    Stehlin F; Ribi C
    Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real World treatment patterns of hereditary angioedema with lanadelumab in Germany: A prescription data analysis.
    Martinez-Saguer I; Knop J; Flemming A; Thomann M; Maurer M
    J Dtsch Dermatol Ges; 2022 Aug; 20(8):1127-1129. PubMed ID: 35913113
    [No Abstract]   [Full Text] [Related]  

  • 14. A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat.
    Kelbel T
    Ann Allergy Asthma Immunol; 2022 Apr; 128(4):462-463. PubMed ID: 35063629
    [No Abstract]   [Full Text] [Related]  

  • 15. A review of berotralstat for the treatment of hereditary angioedema.
    Farkas H; Balla Z
    Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
    Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
    Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom.
    Ahuja M; Dorr A; Bode E; Boulton APR; Buckland M; Chee S; Dalley C; Denman S; Ekbote A; Elkhalifa S; El-Shanawany T; Eren E; Herwadkar A; Garcez T; Ghanta H; Grammatikos A; Grigoriadou S; Jain R; Lorenzo L; Manson A; Moon E; Murng S; Murphy A; Mutlu L; Peters N; Sooriyakumar K; Stroud C; Townsend K; Yellon RL; Yong P; Kiani-Alikhan S
    Allergy; 2023 May; 78(5):1380-1383. PubMed ID: 36609839
    [No Abstract]   [Full Text] [Related]  

  • 20. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
    Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
    Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.